True North raises $40 mln

By Luisa Beltran — 2 months ago

True North Therapeutics said Thursday that it completed a $40 million Series C equity financing led by New Leaf Venture Partners. Also participating were Perceptive Advisors and Cowen Private Investments, as well as existing investors Kleiner Perkins Caufield & Byers, MPM Capital, OrbiMed, SR One and Baxalta Ventures. San Francisco-based True North is a clinical stage biotechnology company.

Continue

Deciphera Pharma raises $75 mln

By Luisa Beltran — 5 months ago

Deciphera Pharmaceuticals said Monday it closed a $75 million Series B financing led by New Leaf Venture Partners and joined by Deciphera’s existing investors. Waltham, Massachusetts-based Deciphera a clinical-stage biotechnology company.

Continue

New Leaf Venture leads $25 mln funding in Kyruus

By Chris Witkowsky — 5 months ago

New Leaf Venture Partners led a $25 million funding round in Kyruus, an enterprise software company for hospitals. Other investors in the funding included Providence Health & Services, Leerink Capital Partners and McKesson Ventures. Existing investors Venrock, Highland Capital Partners, Lux Capital and Fidelity Biosciences also participated in the funding. Sam Brasch, venture partner at New Leaf, has joined Kyruus’ board.

Continue

Kyruus nabs $25 mln

By Iris Dorbian — 5 months ago

Boston-based Kyruus, an enterprise software solutions provider that helps hospitals optimize patient access and referral management, has secured $25 million in funding. New Leaf Venture Partners led the round with participation from Providence Health & Services, Leerink Capital Partners, McKesson Ventures, Venrock, Highland Capital Partners, Lux Capital and Fidelity Biosciences.

Continue

ReShape Medical racks up $38 mln

By Iris Dorbian — 6 months ago

San Clemente, California-based ReShape Medical, a weight loss-focused medical device company, has closed $38 million in Series D funding. HealthCor Partners Management LP led the round with participation from Endeavour Vision SA, SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners and Venture Investors.

Continue

Genetic medicine company WAVE Life Sciences nets $66 mln

By Iris Dorbian — 6 months ago

Boston-based genetic medicine company WAVE Life Sciences has closed $66 million in Series B funding. Foresite Capital led the round with participation from other investors that included Fidelity Management and Research Company, New Leaf Venture Partners, Redmile Group, Jennison Associates (on behalf of certain clients), Cormorant Asset Management and RA Capital Management. Leerink Partners served as the placement agent.

Continue

Advanced Cell Diagnostics rakes in $22 mln

By Iris Dorbian — 8 months ago

Advanced Cell Diagnostics Inc, a developer of cell and tissue-based diagnostic tests for precision medicine, has secured $22 million in Series C funding. Summit Partners led the round with participation from Kenson Ventures, Morningside Ventures and New Leaf Venture Partners. In addition to the funding, Harrison Miller, a managing director at Summit Partners, has been added to ACD’s board of directors.

Continue

New Leaf Venture Partners leads Series B round for Unum Therapeutics

By Iris Dorbian — 8 months ago

Cambridge, Massachusetts-based Unum Therapeutics, a developer of antibody-directed cellular immunotherapy, has closed $65 million in Series B funding. New Leaf Venture Partners led the round with participation from other investors that included Brace Pharma Capital, Cowen Private Investments, Novo A/S, Sabby Management LLC, Wellington Management Company LLP, Fidelity Biosciences, Atlas Venture and Sanofi-Genzyme BioVentures. In addition to the funding, Dr. Liam Ratcliffe, managing director at New Leaf Venture Partners, has been added to Unum’s board of directors.

Continue

Dimension Therapeutics nets $65 mln Series B

By Iris Dorbian — 10 months ago

Cambridge, Massachusetts-based Dimension Therapeutics Inc, which is focused on developing treatments for liver disorders, has closed $65 million in Series B funding. New Leaf Venture Partners led the round with participation from other investors that included Jennison Associates (on behalf of investors), Partner Fund Management, RA Capital Management, Rock Springs Capital, Tourbillon Global Ventures, Fidelity Biosciences and OrbiMed. In addition to the funding, Dr. Mike Dybbs, a partner at New Leaf Venture Partners, has been added to Dimension’s board of directors.

Continue

Edge Therapeutics racks up about $72.5 mln

By Iris Dorbian — 10 months ago

Berkeley Heights, New Jersey-based Edge Therapeutics, a biotech company focused on developing therapies for neurological conditions, has secured about $72.5 million in funding from two recent rounds. The company just closed $56 million in a Series C-2 funding round led by Venrock with participation from other investors that included Sofinnova Ventures, Janus Capital Management LLC, New Leaf Venture Partners and BioMed Ventures. The earlier round, which closed in December 2014, raised $16.5 million in Series C-1 funding. The investors for that round were not named. In connection to the Series C-2 round, Dr. Anders Hove of Venrock and Dr. James Healy, a managing partner at Sofinnova Ventures, have been added to Edge Therapeutics’ board of directors.

Continue

CardioKinetix racks up $50 mln

By Iris Dorbian — 1 year ago

CardioKinetix, a Menlo Park, Calif.-based medical device firm, has received $50 million in funding. Edwards Lifesciences Corp. led the round with participation from return backers U.S. Venture Partners, Tekla Healthcare Investors, Tekla Life Sciences Investors, SV Life Sciences, Panorama Capital, New Leaf Venture Partners and Lexington Private Equity. CardioKinetix has also inked an agreement with Edwards Lifesciences Corp. that gives the latter company the option to acquire CardioKinetix “based on future regulatory milestones.”

Continue

Truveris nets $12.75 mln Series C

By Iris Dorbian — 2 years ago

Truveris said Friday that it has closed $12.75 million in Series C funding. Canaan Partners led the round with participation from return backers New Leaf Venture Partners, Tribeca Venture Partners, New Atlantic Ventures and First Round. Based in New York City, Truveris is a platform for pharmacy pricing and benefits analysis.

Continue

QPID Health nets $12.3 mln Series B funds

By Iris Dorbian — 2 years ago

QPID Health said Tuesday that it has raised $12.3 million in Series B funding. New Leaf Venture Partners led the round. In conjunction with the funding, Philippe Chambon, managing director at New Leaf Venture Partners, has been added to QPID Health’s board of directors. Headquartered in Boston, QPID Health is a provider of clinical intelligence to healthcare providers.

Continue

Boston biotech firm Intarcia snags $200 mln

By Iris Dorbian — 2 years ago

Boston-based biotech company Intarcia Therapeutics has raised $200 million financing. RA Capital led the round with participation from investors that include Farallon Capital Management, Foresite Capital, Franklin Templeton, Fred Alger Management, New Leaf Venture Partners and Quilvest.

Continue

VC-backed Versartis raises $126 mln for IPO

By Iris Dorbian — 2 years ago

Versartis has launched its IPO after pricing its 6 million shares at $21 per share. The stock began trading Friday on the NASDAQ under the ticker symbol “VSAR.” Morgan Stanley and Citigroup are the lead underwriters. Based in Redwood City, Calif., Versartis is an endocrine-focused biopharmaceutical company focused on treating growth hormone deficiency. Its backers include Sofinnova Ventures, Aisling Capital, New Leaf Venture Partners and Advent Life Sciences.

Continue

CardioKinetix Completes $48 Million Series E Round

By Connie Loizos — 3 years ago

CardioKinetix, a Menlo Park, Calif.-based medical device company, has completed the $23 million second-tranche of its Series E financing, bringing the total round to $48 million. Panorama Capital is the company’s newest investor. It joins previous investors U.S. Venture Partners, JPMorgan Partners, New Leaf Venture Partners, SV Life Sciences, H&Q Healthcare Investors, and H&Q Life Sciences Investors.

Continue